Decoy Therapeutics is a pre-clinical biotech that completed its transformation from Salarius Pharmaceuticals into a peptide conjugate platform company in November 2025, merging its small molecule oncology assets with Decoy's AI-driven antiviral design engine. The strategic bet is that the combined IMP3ACT platform can generate Designable Multi-Antivirals fast enough to monetize before the next respiratory pandemic, using a fusion-inhibition approach that targets the conserved machinery shared across enveloped virus families.
The load-bearing number is the cash runway, and it is the defining constraint on the entire equity story. The company held $8.3 million in cash at the end of the second quarter, of which a substantial portion is restricted under a Gates Foundation grant and unavailable for general operations. Against a burn rate that ran at a multi-million dollar pace in the first half of 2026, the company's own disclosure places its funding horizon at "late 2026," a window that closes within months.
The second quarter print showed a net loss of $2.4 million on a modest grant revenue line, a marked increase from the prior year quarter, though the year-ago figure was depressed by the absence of post-merger operating costs. The trajectory of that loss relative to the cash burn rate is the single most important dynamic for existing holders. The forward question is whether the DCOY101 pan-coronavirus program can reach a Phase 2 human challenge trial on the strength of non-dilutive funding alone, or whether the next financing round arrives at a valuation that makes the existing equity structure untenable.